Replies to post #169514 on Biotech Values

[poorgradstudent]

GERN:

1) My point is that AF is picking up on a valid and important point. They aren't reporting an (the?!) important clinical parameter in this disease. And in most biotech, but especially GERN, unmentioned important parameters that they leave out are ones that don't look very good.

From reading the abstract I thought it indicated accurately what was achieved and what wasn't achieved. They noted spleen size at entry but made no mention of size reduction following treatment, so we can safely assume no spleen responses.

I guess my point is that things look deceptive not from what was written in the abstract, but because people like AF jumped on an incorrect interpretation without paying attention. AF is picking up on a point that he himself created through his own confusion.

I'm not excited about the drug personally, but I'm not sure that the abstract is misleading.